European Commission granted Orphan Drug Designation to UCART22 for the treatment of ALL June 11, 2024
Immutep and MSD to Evaluate Efti in Combination with KEYTRUDA in Pivotal Ph 3 TACTI-004 Trial June 11, 2024
Positive Topline Results from Ph 2 PICCOLO Trial of Mirvetuximab Soravtansine (ELAHERE) for High FRα Expressing Platinum-Sensitive Ovarian Cancer Announced June 11, 2024
Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer June 11, 2024
Tagrisso with the addition of chemo recommended for approval in the EU by CHMP for patients with EGFR-mutated advanced lung cancer June 11, 2024
FibroGen Announces Clinical Trial Supply Agreement with Regeneron to Evaluate FG-3165 and FG-3175 in Combination with LIBTAYO in Upcoming Clinical Trials June 11, 2024
Champions Oncology and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development June 11, 2024
Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform June 11, 2024
QUANTRO Therapeutics Reaches A Milestone In The Collaboration With Boehringer Ingelheim To Develop First-In-Class Cancer Treatments June 11, 2024
I-Mab Announces Collaboration with BMS to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers June 11, 2024
Notice of Allowance issued for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer June 11, 2024
Alphamab Oncology Collaborated with ArriVent in relation to the Research, Development and Commercialization of ADC Products June 11, 2024
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608 June 11, 2024
Ph 1 Trial of Menin Inhibitor HMPL-506 Initiated in Patients with Hematological Malignancies in China June 11, 2024
Tisotumab Vedotin Ph 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic HNSCC June 11, 2024
3-Year Data For mRNA-4157 (V940) + KEYTRUDA Demonstrated Sustained Improvement in RFS & Distant MFS vs KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection June 11, 2024
FAILED TRIAL: Uproleselan failed to demonstrate significant OS improvement for patients with primary refractory AML in pivotal Ph 3 trial June 11, 2024
Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Trial of RP1 + Nivolumab in Anti-PD1 Failed Melanoma Announced June 11, 2024
FDA clears IND for Ph 1/2a trial (TCX-101) of BSB-1001 for patients with R/R AML, ALL and MDS, in conjunction with alloHSCT June 11, 2024
IND Filing for PFL-002/VERT-002 for Patients with Solid Tumors Including NSCLC with MET Alterations June 11, 2024
FDA Approved Ph 2/3 Study of KPG-121 + Abiraterone combination as 1L Treatment for metastatic CRPC June 11, 2024
